Hybrid branded drugs approved through the US 505(b)(2) regulatory pathway, as well as biosimilars, will be at the forefront of Amneal’s attempts to restore growth by focusing on higher-value, less-competitive opportunities, according to the US firm’s co-founder Chintu Patel, who has just regained control of the company’s direction, along with his older brother Chirag.
Highlighting Amneal’s goal of launching 15 complex generics over the next 24 months, Chintu, 47 – who will focus mainly...








